Flecainide
Flecainide (flecainide) is a small molecule pharmaceutical. Flecainide was first approved as Tambocor on 1985-10-31. It is used to treat atrial fibrillation, cardiac arrhythmias, supraventricular tachycardia, and ventricular tachycardia in the USA. It is known to target potassium voltage-gated channel subfamily A member 1, potassium voltage-gated channel subfamily A member 5, potassium voltage-gated channel subfamily A member 2, voltage-gated potassium channel KCNC1, and potassium voltage-gated channel subfamily A member 7.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| cardiovascular diseases | D002318 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Flecainide (discontinued: Flecainide, Tambocor)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| flecainide acetate | ANDA | 2025-09-23 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
69 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | 3 | 9 | 14 | 22 | 47 |
| Cardiac arrhythmias | D001145 | EFO_0004269 | I49.9 | — | 1 | 3 | 1 | 3 | 8 |
| Ventricular tachycardia | D017180 | — | I47.2 | — | 1 | 1 | 3 | 2 | 7 |
| Tachycardia | D013610 | — | R00.0 | — | — | 1 | 3 | 2 | 6 |
| Premature birth | D047928 | EFO_0003917 | O60 | — | 2 | — | 1 | 2 | 5 |
| Ventricular premature complexes | D018879 | — | I49.3 | — | 1 | — | 2 | 2 | 5 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | 1 | 1 | 1 | 3 |
| Brugada syndrome | D053840 | Orphanet_130 | I49.8 | — | — | — | 1 | 2 | 3 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | 1 | 2 | — | 1 | 4 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | 1 | 2 | — | 1 | 4 |
| Supraventricular tachycardia | D013617 | — | I47.1 | — | — | 1 | — | 2 | 3 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | — | 1 | — | 1 | 2 |
| Recurrence | D012008 | — | — | — | 1 | 1 | — | 1 | 2 |
| Atrial flutter | D001282 | EFO_0003911 | — | — | — | 1 | — | 1 | 2 |
| Coronary disease | D003327 | — | — | — | — | 2 | — | — | 2 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | 2 | — | — | 2 |
| Heart arrest | D006323 | EFO_0009492 | I46 | — | — | 2 | — | — | 2 |
| Ischemic stroke | D000083242 | — | — | — | — | 2 | — | — | 2 |
Show 7 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cardiomyopathies | D009202 | EFO_0000318 | I42 | — | 1 | — | — | 2 | 3 |
| Syndrome | D013577 | — | — | — | 1 | — | — | 2 | 3 |
| Arrhythmogenic right ventricular dysplasia | D019571 | Orphanet_247 | I42.8 | — | 1 | — | — | 1 | 2 |
| Premature cardiac complexes | D005117 | — | I49.40 | — | 1 | — | — | 1 | 2 |
| Sleepiness | D000077260 | — | R40.0 | — | 2 | — | — | — | 2 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 1 | — | — | — | 1 |
| Disorders of excessive somnolence | D006970 | — | G47.1 | — | 1 | — | — | — | 1 |
| Narcolepsy | D009290 | EFO_0000614 | G47.4 | — | 1 | — | — | — | 1 |
| Blood pressure | D001794 | EFO_0004325 | — | — | 1 | — | — | — | 1 |
| Pain | D010146 | EFO_0003843 | R52 | — | 1 | — | — | — | 1 |
Show 2 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sleep deprivation | D012892 | — | F51.12 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 1 | 1 |
| Drug interactions | D004347 | — | — | — | — | — | — | 1 | 1 |
| Cognitive dysfunction | D060825 | — | G31.84 | — | — | — | — | 1 | 1 |
| Left ventricular dysfunction | D018487 | — | — | — | — | — | — | 1 | 1 |
| Ventricular dysfunction | D018754 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Flecainide |
| INN | flecainide |
| Description | Flecainide is a monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart). It has a role as an anti-arrhythmia drug. It is a monocarboxylic acid amide, a member of piperidines, an organofluorine compound and an aromatic ether. It is a conjugate base of a flecainide(1+). |
| Classification | Small molecule |
| Drug class | Ic antiarrhythmic |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C(NCC1CCCCN1)c1cc(OCC(F)(F)F)ccc1OCC(F)(F)F |
Identifiers
| PDB | — |
| CAS-ID | 54143-55-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL652 |
| ChEBI ID | 75984 |
| PubChem CID | 3356 |
| DrugBank | DB01195 |
| UNII ID | K94FTS1806 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
KCNC1
KCNC1
Organism
Homo sapiens
Gene name
KCNC1
Gene synonyms
NCBI Gene ID
Protein name
potassium voltage-gated channel subfamily C member 1
Protein synonyms
NGK2, potassium channel, voltage gated Shaw related subfamily C, member 1, voltage-gated potassium channel protein KV3.1, Voltage-gated potassium channel subunit Kv3.1, Voltage-gated potassium channel subunit Kv4
Uniprot ID
Mouse ortholog
Kcnc1 (16502)
potassium voltage-gated channel subfamily C member 1 (P15388)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Flecainide
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 7,540 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
5,622 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use